Skip to Content
Merck
CN

SML1921

NVP-ADW742

≥98% (HPLC)

Synonym(s):

5-[3-(Phenylmethoxy)phenyl]-7-[trans-3-(1-pyrrolidinylmethyl)cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, NVP-ADW 742

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C28H31N5O
CAS Number:
475488-23-4
Molecular Weight:
453.58
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

NVP-ADW742, ≥98% (HPLC)

SMILES string

N6(CCCC6)C[C@@H]1C[C@H](C1)[n]2c3ncnc(c3c(c2)c4cc(ccc4)OCc5ccccc5)N

InChI

1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)/t21-,23-

InChI key

LSFLAQVDISHMNB-AFARHQOCSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Application

NVP-ADW742 has been used as an insulin-like growth factor 1 receptor (IGF1R) inhibitor to test the effects of filamin A (FLNA) silencing in a cell proliferation assay.

Biochem/physiol Actions

Insulin-like growth factor-I (IGF-I) receptor kinase inhibitor
NVP-ADW742 is a potent and selective ATP-competitive inhibitor of Insulin-like growth factor-I receptor (IGF-IR) kinase. NVP-ADW742 sensitizes cancer cell lines to multiple anticancer agents including etoposide, carboplatin, imatinib, vincristine, and doxorubicin.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000473881
0000473881
0000469123
0000469123
0000139314

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Catalano et al.
Cancer letters, 497, 77-88 (2020-10-20)
Adrenocortical carcinomas (ACCs) overexpress insulin-like growth factor 2 (IGF2), that drives a proliferative autocrine loop by binding to IGF1R and IR, but IGF1R/IR-targeted therapies failed in ACC patients. The cytoskeleton actin-binding protein filamin A (FLNA) impairs IR signalling in melanoma

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service